SAN DIEGO (EGMN) - A provocative analysis suggests that a sequence of two novel agents provides a better survival advantage than regimens with three or more agents in patients with multiple myeloma and high-risk cytogenetics."While the limitations of this retrospective study limit drawing definitive conclusions, it appears that poor cytogenetics and biology trump treatment intensification," Dr. Rachid Baz and his colleagues stated in a poster presentation at the annual meeting of the American Society...